Mentions
Extended reach
Total likes
Video views
AI synopsis
The overall tone is highly positive, with several examples illustrating this, such as mentions of the significant reduction in proteinuria and references to clinical trials in reputable journals. Words like 'clinically meaningful,' 'progress,' and 'breakthrough' highlight enthusiasm and confidence in the study’s implications, reflecting a collective belief in its potential impact on treatment for IgA nephropathy.
Most discussions express strong support and approval for the study and its findings that Iptacopan significantly reduces proteinuria in IgA nephropathy.
The posts show high curiosity and engagement, often mentioning clinical significance and potential as a breakthrough treatment.
Many posts delve into details like trial results, biological mechanisms, and safety, indicating deep involvement.
The widespread sharing of research articles and positive tone suggests these discussions could influence clinical practices and future research directions.
Among patients with IgA nephropathy, treatment with iptacopan, which inhibits the alternative complement pathway, resulted in a significant reduction in proteinuria as compared with placebo. Full APPLAUSE-IgAN trial results and Research Summary: https://t.co/1ajUiNwQtB https://t.co/34qDQu8wGc
Original Article: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy (APPLAUSE-IgAN) https://t.co/1ajUiNwQtB Editorial: Waystations in Progress — Burgeoning Treatment Options for IgA Nephropathy https://t.co/YgQWm4Bym2 #KidneyWk | @ASNKidney https://t.co/EmgQn3wyvS
Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy | New England Journal of Medicine https://t.co/zFE1OdUpTs
En nefropatía por IgA y proteinuria >1gr, iptacopan (inhibidor de via alterna del complemento), comparado a placebo, ↓38% proteinuria y los biomarcadores de la activación del complemento. Además fue seguro Ensayo clínico APPLAUSE-IgAN #ISNyoung NEJM 2024 10.1056/NEJMoa2410316 https://t.co/nan2M5Gm7d
New in the February 6, 2025, issue of NEJM: Iptacopan in IgA Nephropathy (APPLAUSE-IgAN phase 3 trial) https://t.co/1ajUiNwiE3 Atrasentan in Patients with IgA Nephropathy (ALIGN phase 3 trial) https://t.co/hiN1IlZrpq Liraglutide for Children with Obesity (SCALE Kids phase https://t.co/rhN7rAi0vt
Original Article: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy (APPLAUSE-IgAN phase 3 trial) https://t.co/1ajUiNwQtB Editorial: Way Stations in Progress — Burgeoning Treatment Options for IgA Nephropathy https://t.co/YgQWm4Bym2 #Nephrology https://t.co/x1UO1HFch5
Explore the latest advancements in kidney care from American Kidney Week 2024, highlighting new medications, dialysis technologies, and stem cell research aimed at reducing proteinuria and improving kidney function.
The second part of our 2025 internist annual review presents the top nephrology and hypertensiology studies of 2025, featuring experts from across Europe discussing recent developments and key clinical trials.
この辺も． https://t.co/IdxqgZIafz https://t.co/x6czHvIeZ2
RT @drbennisahmed: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy treatment with iptacopan resulted in a sign…
Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy treatment with iptacopan resulted in a significant and clinically meaningful reduction in proteinuria as compared with placebo https://t.co/31Fjt0LjGD https://t.co/EVTiBLRR3k
RT @gasu2019koto: IgA腎症におけるイプタコパンのP3。9カ月後のTP/Crをプラセボと比較して有意に改善。有害事象に差なし。 補体B因子阻害薬で、C3転換酵素を阻害することになるので代替経路から下流のC5転換酵素形成も阻害することに。腎機能自体の評価は別の試…
Facilitated our Journal Club today on APPLAUSE-IgAN Trial’s interim analysis.
Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy https://t.co/vhhrRdSylR IgA nephropathy, treatment with iptacopan resulted in a significant and clinically meaningful reduction in proteinuria as compared with placebo @juniorjuri @jamesunited8
RT @SeeFisch: IPTACOPAN IS A COMPLEMENT INHIBITOR SEEMS TO REALLY DECREASE PROTEINURIA IN IgA NEPHROPATHY Alternative Complement Pathway I…
Iptacopan significantly reduced proteinuria in IgA nephropathy patients, demonstrating its efficacy without unexpected safety concerns. by Perkovic V, Barratt J (...) Rizk DV et 12 al. in N Engl J Med #MedSky
Iptacopan significantly reduced proteinuria in IgA nephropathy patients, demonstrating its efficacy without unexpected safety concerns. by Perkovic V, Barratt J (...) Rizk DV et 12 al. in N Engl J Med https://t.co/XW2lz03RwD #MedX #MedResearch
Inhibición alternativa de la vía del complemento con iptacopan en la nefropatía por IgA | Revista de Medicina de Nueva Inglaterra https://t.co/ghMsV72J5w
Phase 3 trial shows Iptacopan effectively targets factor B to inhibit the alternative complement pathway in IgA nephropathy. Will this be the next breakthrough? #IgANephropathy PMID:39453772, N Engl J Med 2025, @NEJM https://t.co/RJbUDGGvjO
Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy Among patients with IgA nephropathy, treatment with iptacopan resulted in a significant and clinically meaningful reduction in proteinuria https://t.co/31Fjt0LjGD https://t.co/jmql0unxE6
RT @NEJM: Among patients with IgA nephropathy, treatment with iptacopan, which inhibits the alternative complement pathway, resulted in a s…
Among patients with IgA nephropathy, treatment with iptacopan, which inhibits the alternative complement pathway, resulted in a significant reduction in proteinuria as compared with placebo. Full APPLAUSE-IgAN trial results and Research Summary: nej.md/3UmrOkh #MedSky #Nephrology
RT @NEJM: Among patients with IgA nephropathy, treatment with iptacopan, which inhibits the alternative complement pathway, resulted in a s…
RT @NEJM: Among patients with IgA nephropathy, treatment with iptacopan, which inhibits the alternative complement pathway, resulted in a s…
Inhibición alternativa de la vía del complemento con iptacopan en la nefropatía por IgA | Revista de Medicina de Nueva Inglaterra https://t.co/ghMsV72J5w
RT @NEJM: Among patients with IgA nephropathy, treatment with iptacopan, which inhibits the alternative complement pathway, resulted in a s…
RT @NEJM: Among patients with IgA nephropathy, treatment with iptacopan, which inhibits the alternative complement pathway, resulted in a s…
RT @NEJM: Among patients with IgA nephropathy, treatment with iptacopan, which inhibits the alternative complement pathway, resulted in a s…
RT @NEJM: Among patients with IgA nephropathy, treatment with iptacopan, which inhibits the alternative complement pathway, resulted in a s…
RT @NEJM: Among patients with IgA nephropathy, treatment with iptacopan, which inhibits the alternative complement pathway, resulted in a s…
Among patients with IgA nephropathy, treatment with iptacopan, which inhibits the alternative complement pathway, resulted in a significant reduction in proteinuria as compared with placebo. Full APPLAUSE-IgAN trial results and Research Summary: https://t.co/1ajUiNwQtB https://t.co/34qDQu8wGc
RT @NEJM: Original Article: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy (APPLAUSE-IgAN phase 3 trial) https…
RT @NEJM: Original Article: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy (APPLAUSE-IgAN phase 3 trial) https…
RT @NEJM: Original Article: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy (APPLAUSE-IgAN phase 3 trial) https…
RT @NEJM: Original Article: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy (APPLAUSE-IgAN phase 3 trial) https…
RT @NEJM: Original Article: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy (APPLAUSE-IgAN phase 3 trial) https…
RT @NEJM: Original Article: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy (APPLAUSE-IgAN phase 3 trial) https…
RT @NEJM: Original Article: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy (APPLAUSE-IgAN phase 3 trial) https…
RT @NEJM: Original Article: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy (APPLAUSE-IgAN phase 3 trial) https…
RT @NEJM: Original Article: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy (APPLAUSE-IgAN phase 3 trial) https…
RT @mmacia25: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy | New England Journal of Medicine https://t.co/0D…
RT @NEJM: Original Article: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy (APPLAUSE-IgAN phase 3 trial) https…
RT @NEJM: Original Article: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy (APPLAUSE-IgAN phase 3 trial) https…
Original Article: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy (APPLAUSE-IgAN phase 3 trial) https://t.co/1ajUiNwQtB Editorial: Way Stations in Progress — Burgeoning Treatment Options for IgA Nephropathy https://t.co/YgQWm4Bym2 #Nephrology https://t.co/x1UO1HFch5
RT @manuelmuro5: Entre los pacientes con nefropatía por IgA, el tratamiento con iptacopan produjo una reducción significativa y clínicament…
RT @mmacia25: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy | New England Journal of Medicine https://t.co/0D…
RT @NEJM: New in the February 6, 2025, issue of NEJM: Iptacopan in IgA Nephropathy (APPLAUSE-IgAN phase 3 trial) https://t.co/1ajUiNwiE3…
RT @mmacia25: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy | New England Journal of Medicine https://t.co/0D…
RT @NEJM: New in the February 6, 2025, issue of NEJM: Iptacopan in IgA Nephropathy (APPLAUSE-IgAN phase 3 trial) https://t.co/1ajUiNwiE3…
RT @NEJM: New in the February 6, 2025, issue of NEJM: Iptacopan in IgA Nephropathy (APPLAUSE-IgAN phase 3 trial) https://t.co/1ajUiNwiE3…
RT @NEJM: New in the February 6, 2025, issue of NEJM: Iptacopan in IgA Nephropathy (APPLAUSE-IgAN phase 3 trial) https://t.co/1ajUiNwiE3…
RT @NEJM: New in the February 6, 2025, issue of NEJM: Iptacopan in IgA Nephropathy (APPLAUSE-IgAN phase 3 trial) https://t.co/1ajUiNwiE3…
RT @NEJM: New in the February 6, 2025, issue of NEJM: Iptacopan in IgA Nephropathy (APPLAUSE-IgAN phase 3 trial) https://t.co/1ajUiNwiE3…
RT @NEJM: New in the February 6, 2025, issue of NEJM: Iptacopan in IgA Nephropathy (APPLAUSE-IgAN phase 3 trial) https://t.co/1ajUiNwiE3…
RT @SeeFisch: IPTACOPAN IS A COMPLEMENT INHIBITOR SEEMS TO REALLY DECREASE PROTEINURIA IN IgA NEPHROPATHY Alternative Complement Pathway I…
Entre los pacientes con nefropatía por IgA, el tratamiento con iptacopan produjo una reducción significativa y clínicamente significativa de la proteinuria en comparación con placebo. https://t.co/MJ8HcdYJdd
RT @NEJM: New in the February 6, 2025, issue of NEJM: Iptacopan in IgA Nephropathy (APPLAUSE-IgAN phase 3 trial) https://t.co/1ajUiNwiE3…
RT @NEJM: New in the February 6, 2025, issue of NEJM: Iptacopan in IgA Nephropathy (APPLAUSE-IgAN phase 3 trial) https://t.co/1ajUiNwiE3…
RT @NEJM: New in the February 6, 2025, issue of NEJM: Iptacopan in IgA Nephropathy (APPLAUSE-IgAN phase 3 trial) https://t.co/1ajUiNwiE3…
New in the February 6, 2025, issue of NEJM: Iptacopan in IgA Nephropathy (APPLAUSE-IgAN phase 3 trial) https://t.co/1ajUiNwiE3 Atrasentan in Patients with IgA Nephropathy (ALIGN phase 3 trial) https://t.co/hiN1IlZrpq Liraglutide for Children with Obesity (SCALE Kids phase https://t.co/rhN7rAi0vt
New in the February 6, 2025, issue of NEJM: Iptacopan in IgA Nephropathy (APPLAUSE-IgAN phase 3 trial) https://t.co/1ajUiNwQtB Atrasentan in Patients with IgA Nephropathy (ALIGN phase 3 trial) https://t.co/hiN1IlZZeY Liraglutide for Children with Obesity (SCALE Kids phase https://t.co/uy6th3pkzs
New treatments for Berger's disease: https://t.co/pUWIAvfyXV & https://t.co/F317bhtOBo (full disclosure- neither I nor anyone in my family had anything to do with the "Berger's disease" name for IgA nephropathy)
“Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy.” Publié ce jour dans @nejm.org. #Medsky #Nephrology www.nejm.org/doi/full/10....
IPTACOPAN IS A COMPLEMENT INHIBITOR SEEMS TO REALLY DECREASE PROTEINURIA IN IgA NEPHROPATHY Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy | New England Journal of Medicine https://t.co/lXc0sz38rG
Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy https://t.co/0PGrWrxGkI
Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy | New England Journal of Medicine https://t.co/0DQXAzddCs
IgA腎症におけるイプタコパンのP3。9カ月後のTP/Crをプラセボと比較して有意に改善。有害事象に差なし。 補体B因子阻害薬で、C3転換酵素を阻害することになるので代替経路から下流のC5転換酵素形成も阻害することに。腎機能自体の評価は別の試験が進行中（学会発表された？） https://t.co/i4Zt63acY3
RT @MarkusAtHome: TOP 11: APPLAUSE by Drs. @VladoPerkovic, @DanaRizk1 et al. https://t.co/nEj8RlCtQr Among patients with IgA nephropathy,…
TOP 11: APPLAUSE by Drs. @VladoPerkovic, @DanaRizk1 et al. https://t.co/nEj8RlCtQr Among patients with IgA nephropathy, Iptacopan (an inhibitor of the alternative complement pathway) induced a clinically meaningful reduction in proteinuria compared to placebo. https://t.co/s3FWNHrRrU
RT @dgfn_ev: Hope for IgA Nephropathy: Iptacopan: 38.3% proteinuria reduction: https://t.co/hWQXn5xSqZ Atrasentan: 36.1% reduction: https…
Hope for IgA Nephropathy: Iptacopan: 38.3% proteinuria reduction: https://t.co/hWQXn5xSqZ Atrasentan: 36.1% reduction: https://t.co/3EqDAAPsJf These therapies mark progress toward better outcomes for patients. #KidneyHealth #IgANephropathy https://t.co/LTPp64I8BH
RT @JonathanNefro: En nefropatía por IgA con proteinuria >1gr, Iptacopan (inhibidor de la vía alterna del complemento), comparado a placebo…
RT @joeMD77: Inhibición Vía alterna del C´con IPTACOPAN en IgAN ◻️Se une a factor B ❌ vía alterna ◻️ECA 443
Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy | New England Journal of Medicine https://t.co/WfhP66ffSq
RT @joeMD77: Inhibición Vía alterna del C´con IPTACOPAN en IgAN ◻️Se une a factor B ❌ vía alterna ◻️ECA 443
RT @joeMD77: Inhibición Vía alterna del C´con IPTACOPAN en IgAN ◻️Se une a factor B ❌ vía alterna ◻️ECA 443
RT @joeMD77: Inhibición Vía alterna del C´con IPTACOPAN en IgAN ◻️Se une a factor B ❌ vía alterna ◻️ECA 443
Inhibición Vía alterna del C´con IPTACOPAN en IgAN ◻️Se une a factor B ❌ vía alterna ◻️ECA 443
Congratulations Dr. Dana Rizk @DanaRizk1 @UAB_NRTC!!!
RT @gunnar_heine: APPLAUSE, APPLAUSE @VladoPerkovic @IgAN_JBarratt @BradRovin et al Iptacopan reduces proteinurie (PU) in IgA NP
RT @JonathanNefro: En nefropatía por IgA y proteinuria >1gr, iptacopan (inhibidor de via alterna del complemento), comparado a placebo, ↓38…
RT @JonathanNefro: En nefropatía por IgA y proteinuria >1gr, iptacopan (inhibidor de via alterna del complemento), comparado a placebo, ↓38…
RT @DanaRizk1: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy | New England Journal of Medicine https://t.co/z…
Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy #science #publication #research #journal https://t.co/SHe3ukihbN
RT @NEJM: Original Article: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy (APPLAUSE-IgAN) https://t.co/1ajUiN…
RT @JonathanNefro: En nefropatía por IgA y proteinuria >1gr, iptacopan (inhibidor de via alterna del complemento), comparado a placebo, ↓38…
RT @DanaRizk1: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy | New England Journal of Medicine https://t.co/z…
RT @JonathanNefro: En nefropatía por IgA y proteinuria >1gr, iptacopan (inhibidor de via alterna del complemento), comparado a placebo, ↓38…
RT @DanaRizk1: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy | New England Journal of Medicine https://t.co/z…
RT @JonathanNefro: En nefropatía por IgA y proteinuria >1gr, iptacopan (inhibidor de via alterna del complemento), comparado a placebo, ↓38…
RT @DanaRizk1: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy | New England Journal of Medicine https://t.co/z…
RT @DanaRizk1: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy | New England Journal of Medicine https://t.co/z…
RT @JonathanNefro: En nefropatía por IgA y proteinuria >1gr, iptacopan (inhibidor de via alterna del complemento), comparado a placebo, ↓38…
RT @JonathanNefro: En nefropatía por IgA y proteinuria >1gr, iptacopan (inhibidor de via alterna del complemento), comparado a placebo, ↓38…
RT @JonathanNefro: En nefropatía por IgA y proteinuria >1gr, iptacopan (inhibidor de via alterna del complemento), comparado a placebo, ↓38…
RT @JonathanNefro: En nefropatía por IgA y proteinuria >1gr, iptacopan (inhibidor de via alterna del complemento), comparado a placebo, ↓38…
RT @DanaRizk1: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy | New England Journal of Medicine https://t.co/z…
RT @JonathanNefro: En nefropatía por IgA y proteinuria >1gr, iptacopan (inhibidor de via alterna del complemento), comparado a placebo, ↓38…
RT @JonathanNefro: En nefropatía por IgA y proteinuria >1gr, iptacopan (inhibidor de via alterna del complemento), comparado a placebo, ↓38…
RT @JonathanNefro: En nefropatía por IgA y proteinuria >1gr, iptacopan (inhibidor de via alterna del complemento), comparado a placebo, ↓38…
RT @JonathanNefro: En nefropatía por IgA y proteinuria >1gr, iptacopan (inhibidor de via alterna del complemento), comparado a placebo, ↓38…
RT @JonathanNefro: En nefropatía por IgA y proteinuria >1gr, iptacopan (inhibidor de via alterna del complemento), comparado a placebo, ↓38…
En nefropatía por IgA y proteinuria >1gr, iptacopan (inhibidor de via alterna del complemento), comparado a placebo, ↓38% proteinuria y los biomarcadores de la activación del complemento. Además fue seguro Ensayo clínico APPLAUSE-IgAN #ISNyoung NEJM 2024 10.1056/NEJMoa2410316 https://t.co/nan2M5Gm7d
RT @NEJM: Original Article: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy (APPLAUSE-IgAN) https://t.co/1ajUiN…
RT @DanaRizk1: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy | New England Journal of Medicine https://t.co/z…
RT @NEJM: Original Article: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy (APPLAUSE-IgAN) https://t.co/1ajUiN…
RT @NEJM: Original Article: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy (APPLAUSE-IgAN) https://t.co/1ajUiN…
RT @DanaRizk1: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy | New England Journal of Medicine https://t.co/z…
RT @NEJM: Original Article: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy (APPLAUSE-IgAN) https://t.co/1ajUiN…
RT @DanaRizk1: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy | New England Journal of Medicine https://t.co/z…
RT @DanaRizk1: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy | New England Journal of Medicine https://t.co/z…
RT @DanaRizk1: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy | New England Journal of Medicine https://t.co/z…
RT @NEJM: Original Article: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy (APPLAUSE-IgAN) https://t.co/1ajUiN…
RT @JonathanNefro: En nefropatía por IgA con proteinuria >1gr, Iptacopan (inhibidor de la vía alterna del complemento), comparado a placebo…
RT @DanaRizk1: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy | New England Journal of Medicine https://t.co/z…
RT @DanaRizk1: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy | New England Journal of Medicine https://t.co/z…
RT @DanaRizk1: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy | New England Journal of Medicine https://t.co/z…
RT @DanaRizk1: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy | New England Journal of Medicine https://t.co/z…
RT @DanaRizk1: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy | New England Journal of Medicine https://t.co/z…
Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy | New England Journal of Medicine https://t.co/zFE1OdUpTs
RT @NEJM: Original Article: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy (APPLAUSE-IgAN) https://t.co/1ajUiN…
RT @NEJM: Original Article: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy (APPLAUSE-IgAN) https://t.co/1ajUiN…
RT @NEJM: Original Article: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy (APPLAUSE-IgAN) https://t.co/1ajUiN…
RT @NEJM: Original Article: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy (APPLAUSE-IgAN) https://t.co/1ajUiN…
RT @NEJM: Original Article: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy (APPLAUSE-IgAN) https://t.co/1ajUiN…
RT @gunnar_heine: APPLAUSE, APPLAUSE @VladoPerkovic @IgAN_JBarratt @BradRovin et al Iptacopan reduces proteinurie (PU) in IgA NP
RT @NEJM: Original Article: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy (APPLAUSE-IgAN) https://t.co/1ajUiN…
RT @NEJM: Original Article: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy (APPLAUSE-IgAN) https://t.co/1ajUiN…
Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy #science #publication #research #publications https://t.co/8XJp1pTjPB
RT @NEJM: Original Article: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy (APPLAUSE-IgAN) https://t.co/1ajUiN…
https://t.co/udFKKytw4d #iptacopan in #IgAN
RT @NEJM: Original Article: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy (APPLAUSE-IgAN) https://t.co/1ajUiN…
RT @NEJM: Original Article: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy (APPLAUSE-IgAN) https://t.co/1ajUiN…
RT @NEJM: Original Article: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy (APPLAUSE-IgAN) https://t.co/1ajUiN…
RT @NEJM: Original Article: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy (APPLAUSE-IgAN) https://t.co/1ajUiN…
RT @NEJM: Original Article: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy (APPLAUSE-IgAN) https://t.co/1ajUiN…
RT @NEJM: Original Article: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy (APPLAUSE-IgAN) https://t.co/1ajUiN…
RT @NEJM: Original Article: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy (APPLAUSE-IgAN) https://t.co/1ajUiN…
RT @NEJM: Original Article: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy (APPLAUSE-IgAN) https://t.co/1ajUiN…
RT @NEJM: Original Article: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy (APPLAUSE-IgAN) https://t.co/1ajUiN…
RT @NEJM: Original Article: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy (APPLAUSE-IgAN) https://t.co/1ajUiN…
RT @Tobias_B_Huber: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy | New England Journal of Medicine https://t…
RT @NEJM: Original Article: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy (APPLAUSE-IgAN) https://t.co/1ajUiN…
RT @NEJM: Original Article: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy (APPLAUSE-IgAN) https://t.co/1ajUiN…
Presented at ASN: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy | New England Journal of Medicine https://t.co/DOGt597VH6
RT @Tobias_B_Huber: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy | New England Journal of Medicine https://t…
RT @Tobias_B_Huber: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy | New England Journal of Medicine https://t…
RT @NEJM: Original Article: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy (APPLAUSE-IgAN) https://t.co/1ajUiN…
RT @Tobias_B_Huber: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy | New England Journal of Medicine https://t…
RT @NEJM: Original Article: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy (APPLAUSE-IgAN) https://t.co/1ajUiN…
RT @drbennisahmed: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy Among patients with IgA nephropathy, treatm…
RT @NEJM: Original Article: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy (APPLAUSE-IgAN) https://t.co/1ajUiN…
RT @NEJM: Original Article: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy (APPLAUSE-IgAN) https://t.co/1ajUiN…
Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy | New England Journal of Medicine https://t.co/I7geuCuNsi
RT @NEJM: Original Article: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy (APPLAUSE-IgAN) https://t.co/1ajUiN…
RT @NEJM: Original Article: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy (APPLAUSE-IgAN) https://t.co/1ajUiN…
RT @NEJM: Original Article: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy (APPLAUSE-IgAN) https://t.co/1ajUiN…
RT @NEJM: Original Article: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy (APPLAUSE-IgAN) https://t.co/1ajUiN…
Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy - https://t.co/ke83PZj5cC #GoogleAlerts
RT @NEJM: Original Article: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy (APPLAUSE-IgAN) https://t.co/1ajUiN…
RT @NEJM: Original Article: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy (APPLAUSE-IgAN) https://t.co/1ajUiN…
RT @NEJM: Original Article: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy (APPLAUSE-IgAN) https://t.co/1ajUiN…
RT @NEJM: Original Article: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy (APPLAUSE-IgAN) https://t.co/1ajUiN…
Original Article: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy (APPLAUSE-IgAN) https://t.co/1ajUiNwQtB Editorial: Waystations in Progress — Burgeoning Treatment Options for IgA Nephropathy https://t.co/YgQWm4Bym2 #KidneyWk | @ASNKidney https://t.co/EmgQn3wyvS
Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy | New England Journal of Medicine https://t.co/PUcHd4Gnw4
Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy Among patients with IgA nephropathy, treatment with iptacopan resulted in a significant and clinically meaningful reduction in proteinuria https://t.co/31Fjt0LjGD
RT @Tobias_B_Huber: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy | New England Journal of Medicine https://t…
RT @Tobias_B_Huber: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy | New England Journal of Medicine https://t…
RT @KSusztak: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy | @NEJM @VladoPerkovic @IgAN_JBarratt http…
Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy | New England Journal of Medicine https://t.co/xm3DE8O4zH
Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy APPLAUSE-IgAN @NEJM (2024) IgA腎症に対するIptacpanは9ヶ月時点のuPCRをplaceboと比較して38.3%減少 https://t.co/nxIs8Hihwt
RT @KSusztak: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy | @NEJM @VladoPerkovic @IgAN_JBarratt http…
doi: 10.1056/NEJMoa2410316. PubMed. Perkovic V , Alternative complement pathway inhibition with iptacopan in IgA nephropathy . N Engl J Med (published online ...
NEJMは、経口補体第二経路B因子阻害薬Iptacopanの有効性を示したAPPLAUSE-IgAN試験の結果を併載している（https://doi.org/10.1056/NEJMoa2410316）。 両試験の成功 ...
543, 2024 10.1056/NEJMoa2410316 PubMed. Kidney Int 68: 802–812, 2005 10.1111/j.1523-1755.2005.00460.x 119. Barratt J, Liew A, Yeo SC, Fernstr€om A, Barbour ...
No increased risk of infection was observed. Read more: https://www.nejm. org/doi/full/10.1056/NEJMoa2410316 #Iptacopan #FactorBInhibitor #IgAN.
https://nejm.org/doi/abs/10.1056/NEJMoa2410316 https://kidney-international.org/article/S0085-2538%2824%2900236-9/fulltext https ...
DOI : 10.1056/NEJMoa1415463 (4) V. Perkovic et al., NEJM, 2025. DOI : 10.1056/NEJMoa2410316 (5) H. Heerspink et al., NEJM, 2025. DOI ...
Source: nejm.org/doi/full/10.1056/NEJMoa2410316. Related Posts. Large eGFRdiff Signals Much Higher Mortality, CV, & Kidney Risks. Jolynn Tumolo ...
10.1056/NEJMoa2410316. 7. Heerspink HJL, et al. The selective endothelin receptor antagonist SC0062 in IgA nephropathy: A random- ized double ...
https://www.nejm. org/doi/full/10.1056/NEJMoa2409415 https://www.nejm. org/doi/full/10.1056/NEJMoa2410316 https://www.nejm. org/doi/full/10.1056 ...
org/doi/full/10.1056/NEJMoa2409415 https://www.nejm. org/doi/full/10.1056/NEJMoa2410316 https://www.nejm. org/doi/full/10.1056/NEJMe2413288.
10.1056/NEJMoa2410316. 7. Heerspink HJL, et al. The selective endothelin receptor antagonist SC0062 in IgA nephropathy: A random- ized double ...
https://nejm.org/doi/abs/10.1056/NEJMoa2410316 https://kidney-international.org/article/S0085-2538%2824%2900236-9/fulltext https ...
7 likes, 0 comments - dr.paulo.ayroza.galvao on December 18, 2024: "Insulina, uma vez por semana!".
https://nejm.org/doi/abs/10.1056/NEJMoa2410316 https://kidney-international.org/article/S0085-2538%2824%2900236-9/fulltext https ...
... 10.1056/NEJMoa2410316. Secondary Source. New England Journal of Medicine. Source Reference: Ingelfinger JR "Way stations in progress ...
N
DR
JC
賀
N
M
AM
PD
TM
T
CF
SR
DF
SG
XX
?
EP
AG
ما
MM
AL
A
FM
IC
HH
MM
N
DP
AG
M
D
IT
GK
LS
A
RG
DJ
AA
MQ
HC
DR
MM
JG
長腎
SJ
MB
SC
MH
ガに
DV
M
NT
DN
DR
DJ
JM
V
NG
UN
ML
MF
AM
LC
MB
ME
CP
DN
AJ
SQ
KF
EC
DN
JR
V
EA
DB
FZ
RC
D
DM
PF
RL
AF
AA
PC
PB
MH
A
SA
VP
PD
RK
JB
IS
SM
TC
A
DB
NF
LC
CK
DV
BO
G
FG
AB
HM
AH
KM
AB
L
TA
TC
ID
RF
VP
A
RH
JC
CL
GB
SF
BM
NG
JM
FA
CH
IS
AH
DM
TH
R
SG